Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933 · View on ClinicalTrials.gov ↗

Study Summary

This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24 and 2024/25 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.

Interventions

  • BIOLOGICAL Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
  • BIOLOGICAL High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)

Study Locations (1)

California

  • Kaiser Permanente Northern California (entire region) — Oakland

Trial Details

FieldValue
Enrollment Target 960,000 participants
Start Date 2023-08-17
Est. Completion 2026-05

Sponsor

Kaiser Permanente

132 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06029933

The ClinicalTrials.gov registry entry for NCT06029933 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 960,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 132 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Influenza appearing as the primary indexed condition, and to 2 interventions — of which Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06029933 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06029933 about?

NCT06029933 is a clinical study titled "Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years". This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adult...

What is the current status of trial NCT06029933?

This trial is currently recruiting. The enrollment target is 960,000 participants. The study started on 2023-08-17. Estimated completion is 2026-05.

What conditions does trial NCT06029933 study?

This clinical trial studies the following conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06029933?

The interventions under investigation include: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4) (BIOLOGICAL), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4) (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06029933?

This trial is sponsored by Kaiser Permanente, which has 132 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06029933 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial